{"DataElement":{"publicId":"7055162","version":"1","preferredName":"ICD-9 CM/PCS Cause of Death Reason Name","preferredDefinition":"The ICD-9 CM/PCS cancer diagnosis that resulted in a patient death.","longName":"DDRNICD9","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"7050169","version":"1","preferredName":"Death Diagnosis Domain ICD-9-CM/PCS Cause of Death Reason","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to death diagnosis._The International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-9 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding._The circumstance or condition that results in the death of a living being._An explanation of the cause of some phenomenon or action.","longName":"6408103v1.0:7050167v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6408103","version":"1","preferredName":"Death Diagnosis Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to death diagnosis.","longName":"C95087","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Death Diagnosis Domain","conceptCode":"C95087","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to death diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F427A1-41D5-1B4B-E053-F662850A4A5F","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7050167","version":"1","preferredName":"ICD-9-CM/PCS Cause of Death Reason","preferredDefinition":"The International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-9 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.:The circumstance or condition that results in the death of a living being.:An explanation of the cause of some phenomenon or action.","longName":"C154408:C81239:C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICD-9-CM/PCS","conceptCode":"C154408","definition":"The International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-9 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cause of Death","conceptCode":"C81239","definition":"The circumstance or condition that results in the death of a living being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DCD25C-968D-2B86-E053-F662850A03E0","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"ONEDATA","dateModified":"2019-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"96DCD25C-969E-2B86-E053-F662850A03E0","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"KUMMEROA","dateModified":"2020-06-18","changeDescription":"Released. AK 2020-6-10; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2194932","version":"1","preferredName":"Cancer Type ICD9 Text Name","preferredDefinition":"Set of character short names to represent ICD-9 cancer types.","longName":"CA_TP_ICD9_TXT_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Adrenal Cortical Tumor","valueDescription":"ACT - 194.0; Adrenal Cortical Tumor","ValueMeaning":{"publicId":"2572630","version":"1","preferredName":"ACT - 194.0; Adrenal Cortical Tumor","longName":"2572630","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the adrenal gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Adrenal Gland Neoplasm","conceptCode":"C9338","definition":"A primary or metastatic malignant neoplasm affecting the adrenal gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ICD","id":"EC63A462-AAC1-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Bladder","valueDescription":"VES - 188.9; Bladder","ValueMeaning":{"publicId":"2572631","version":"1","preferredName":"VES - 188.9; Bladder","longName":"2572631","preferredDefinition":"A primary or metastatic malignant neoplasm involving the bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bladder Neoplasm","conceptCode":"C9334","definition":"A primary or metastatic malignant neoplasm involving the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC2-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CNS","valueDescription":"BRAIN - 191.9; CNS","ValueMeaning":{"publicId":"2572632","version":"1","preferredName":"BRAIN - 191.9; CNS","longName":"2572632","preferredDefinition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Central Nervous System Neoplasm","conceptCode":"C4627","definition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC3-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CNS-Glioblastoma","valueDescription":"BRAIN-GB - 191.9; CNS-Glioblastoma","ValueMeaning":{"publicId":"2572633","version":"1","preferredName":"BRAIN-GB - 191.9; CNS-Glioblastoma","longName":"2572633","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC4-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CNS-Medulloblastoma","valueDescription":"BRAIN-MB - 191.9; CNS-Medulloblastoma","ValueMeaning":{"publicId":"2572634","version":"1","preferredName":"BRAIN-MB - 191.9; CNS-Medulloblastoma","longName":"2572634","preferredDefinition":"A malignant, invasive embryonal neoplasm arising from the cerebellum. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, large cell medulloblastoma, and medulloblastoma with extensive nodularity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC5-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Breast-Fem","valueDescription":"BR - 174.0; Breast-Fem","ValueMeaning":{"publicId":"2572635","version":"1","preferredName":"BR - 174.0; Breast-Fem","longName":"2572635","preferredDefinition":"A malignant neoplasm that affects the area of the nipple in females.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Female Malignant Nipple Neoplasm","conceptCode":"C120455","definition":"A malignant neoplasm that affects the area of the nipple in females.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC6-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Breast-Male","valueDescription":"BR - 175.0; Breast-Male","ValueMeaning":{"publicId":"2572636","version":"1","preferredName":"BR - 175.0; Breast-Male","longName":"2572636","preferredDefinition":"A malignant neoplasm that affects the area of the nipple in males.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Male Malignant Nipple Neoplasm","conceptCode":"C120454","definition":"A malignant neoplasm that affects the area of the nipple in males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC7-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Breast-LCIS","valueDescription":"BR-LCIS - 233.0; Breast-LCIS","ValueMeaning":{"publicId":"2572637","version":"1","preferredName":"BR-LCIS - 233.0; Breast-LCIS","longName":"2572637","preferredDefinition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Lobular Carcinoma In Situ","conceptCode":"C4018","definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC8-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Breast-DCIS","valueDescription":"BR-DCIS - 233.0; Breast-DCIS","ValueMeaning":{"publicId":"2572638","version":"1","preferredName":"BR-DCIS - 233.0; Breast-DCIS","longName":"2572638","preferredDefinition":"A carcinoma entirely confined to the mammary ducts.  It is also known as DCIS.  There is no evidence of invasion of the basement membrane.  Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis.  The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAC9-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Carcinoma Unknown Primary","valueDescription":"CUPS - 199.1; Carcinoma Unknown Primary","ValueMeaning":{"publicId":"2572639","version":"1","preferredName":"CUPS - 199.1; Carcinoma Unknown Primary","longName":"2572639","preferredDefinition":"A carcinoma which has metastasized from an unknown primary anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma of Unknown Primary","conceptCode":"C3812","definition":"A carcinoma which has metastasized from an unknown primary anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AACA-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cervix","valueDescription":"CX - 180.9; Cervix","ValueMeaning":{"publicId":"2572640","version":"1","preferredName":"CX - 180.9; Cervix","longName":"2572640","preferredDefinition":"Primary or metastatic malignant neoplasm involving the cervix. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Cervical Neoplasm","conceptCode":"C9311","definition":"A primary or metastatic malignant neoplasm involving the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AACB-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cervix-Squamous Cell Carcinoma","valueDescription":"CX-SCC - 180.9; Cervix-Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2572641","version":"1","preferredName":"CX-SCC - 180.9; Cervix-Squamous Cell Carcinoma","longName":"2572641","preferredDefinition":"A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: Conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Squamous Cell Carcinoma","conceptCode":"C4028","definition":"A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AACC-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cervix-Adenocarcinoma","valueDescription":"CX-AD - 180.9; Cervix-Adenocarcinoma","ValueMeaning":{"publicId":"2572642","version":"1","preferredName":"CX-AD - 180.9; Cervix-Adenocarcinoma","longName":"2572642","preferredDefinition":"An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Adenocarcinoma","conceptCode":"C4029","definition":"An adenocarcinoma arising from the endocervical glandular epithelium. It is classified as either human papillomavirus-related or human papillomavirus-independent adenocarcinoma. Histologic variants include usual-type, mucinous, mesonephric, serous, clear cell, and endometrioid adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8CF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AACD-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Colon","valueDescription":"COL - 153.9; Colon","ValueMeaning":{"publicId":"2572643","version":"1","preferredName":"COL - 153.9; Colon","longName":"2572643","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the colon.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Colon Neoplasm","conceptCode":"C9242","definition":"A primary or metastatic malignant neoplasm that affects the colon.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AACE-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Esophagus","valueDescription":"ESOP - 150.9; Esophagus","ValueMeaning":{"publicId":"2572644","version":"1","preferredName":"ESOP - 150.9; Esophagus","longName":"2572644","preferredDefinition":"A primary or metastatic malignant neoplasm involving the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Esophageal Neoplasm","conceptCode":"C7478","definition":"A primary or metastatic malignant neoplasm involving the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AACF-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Eyeball","valueDescription":"EYE - 190.0; Eyeball","ValueMeaning":{"publicId":"2572645","version":"1","preferredName":"EYE - 190.0; Eyeball","longName":"2572645","preferredDefinition":"A malignant neoplasm that affects the iris. This category includes primary iris melanoma and metastatic malignant neoplasms to the iris.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Iris Neoplasm","conceptCode":"C4554","definition":"A malignant neoplasm that affects the iris. This category includes primary iris melanoma and metastatic malignant neoplasms in the iris.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAD0-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Fallopian Tube","valueDescription":"FT - 183.2; Fallopian Tube","ValueMeaning":{"publicId":"2572646","version":"1","preferredName":"FT - 183.2; Fallopian Tube","longName":"2572646","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the fallopian tube.  Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Fallopian Tube Neoplasm","conceptCode":"C7480","definition":"A primary or metastatic malignant neoplasm that affects the fallopian tube.  Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAD1-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Gallbladder","valueDescription":"GB - 156.0; Gallbladder","ValueMeaning":{"publicId":"2572647","version":"1","preferredName":"GB - 156.0; Gallbladder","longName":"2572647","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the gallbladder.  Representative examples include carcinoma, lymphoma, melanoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallbladder Malignant Neoplasm","conceptCode":"C7481","definition":"A primary or metastatic malignant neoplasm that affects the gallbladder.  Representative examples include carcinoma, lymphoma, melanoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAD2-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Gastric","valueDescription":"GAST - 151.9; Gastric","ValueMeaning":{"publicId":"2572649","version":"1","preferredName":"GAST - 151.9; Gastric","longName":"2572649","preferredDefinition":"A primary or metastatic malignant neoplasm involving the stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Gastric Neoplasm","conceptCode":"C9331","definition":"A primary or metastatic malignant neoplasm involving the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAD3-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"GI","valueDescription":"GI - 159.0; GI","ValueMeaning":{"publicId":"2572650","version":"1","preferredName":"GI - 159.0; GI","longName":"2572650","preferredDefinition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Digestive System Neoplasm","conceptCode":"C4890","definition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAD4-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Gynecology-NOS","valueDescription":"GYN-NOS - 183; Gynecology-NOS","ValueMeaning":{"publicId":"2572651","version":"1","preferredName":"GYN-NOS - 183; Gynecology-NOS","longName":"2572651","preferredDefinition":"Cancer of the female reproductive tract, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Female Reproductive System Neoplasm","conceptCode":"C4913","definition":"A primary or metastatic malignant neoplasm involving the female reproductive system.  Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8D8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AAD5-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Head/Face/Neck","valueDescription":"H/N - 195.0; Head/Face/Neck","ValueMeaning":{"publicId":"2572656","version":"1","preferredName":"H/N - 195.0; Head/Face/Neck","longName":"2572656","preferredDefinition":"Cancer that arises in the head or neck region (in the nasal cavity, sinuses, lip, mouth, salivary glands, throat, or larynx [voice box]).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Head and Neck Neoplasm","conceptCode":"C4013","definition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8DD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-10","changeDescription":"Added concept to VM for UPMC/TCGA project. mc 3/10/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC0-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Hodgkins Disease","valueDescription":"HD - 201.0; Hodgkins Disease","ValueMeaning":{"publicId":"2572657","version":"1","preferredName":"HD - 201.0; Hodgkins Disease","longName":"2572657v1.00","preferredDefinition":"An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin's Paragranuloma","conceptCode":"C26956","definition":"An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8DE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/26/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC1-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Intrahepatic Ducts","valueDescription":"BIL - 155.1; Intrahepatic Ducts","ValueMeaning":{"publicId":"2572658","version":"1","preferredName":"BIL - 155.1; Intrahepatic Ducts","longName":"2572658","preferredDefinition":"A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholangiocarcinoma","conceptCode":"C4436","definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8DF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC2-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Kidney-except Pelvis","valueDescription":"REN - 189.0; Kidney-except Pelvis","ValueMeaning":{"publicId":"2572659","version":"1","preferredName":"REN - 189.0; Kidney-except Pelvis","longName":"2572659","preferredDefinition":"A malignant neoplasm that affects the renal parenchyma but not the pelvis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Kidney Neoplasm Except Pelvis","conceptCode":"C120456","definition":"A malignant neoplasm that affects the renal parenchyma but not the pelvis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"COOPERM","dateModified":"2015-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC3-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia-NOS","valueDescription":"LEUK - 208.0; Leukemia-NOS","ValueMeaning":{"publicId":"2572660","version":"1","preferredName":"LEUK - 208.0; Leukemia-NOS","longName":"2572660","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC4-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia-acute lymphocytic leukemia","valueDescription":"ALL - 204.0; Leukemia-acute, lymphocytic leukemia","ValueMeaning":{"publicId":"2572661","version":"1","preferredName":"ALL - 204.0; Leukemia-acute, lymphocytic leukemia","longName":"2572661","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC5-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia-acute monocytic leukemia","valueDescription":"AML - 206.0; Leukemia-acute monocytic leukemia","ValueMeaning":{"publicId":"2572662","version":"1","preferredName":"AML - 206.0; Leukemia-acute monocytic leukemia","longName":"2572662","preferredDefinition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monocytic Leukemia","conceptCode":"C4861","definition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC6-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia-chronic lymphocytic leukemia","valueDescription":"CLL - 204.1; Leukemia-chronic lymphocytic leukemia","ValueMeaning":{"publicId":"2572663","version":"1","preferredName":"CLL - 204.1; Leukemia-chronic lymphocytic leukemia","longName":"2572663","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC7-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia-chronic monocytic leukemia","valueDescription":"CML - 206.1; Leukemia-chronic monocytic leukemia","ValueMeaning":{"publicId":"2572664","version":"1","preferredName":"CML - 206.1; Leukemia-chronic monocytic leukemia","longName":"2572664","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Monocytic Leukemia","conceptCode":"C34774","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC8-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia-hairy cell leukemia","valueDescription":"HCL - 202.4; Leukemia-hairy cell leukemia","ValueMeaning":{"publicId":"2572665","version":"1","preferredName":"HCL - 202.4; Leukemia-hairy cell leukemia","longName":"2572665","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABC9-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Liver-Hepatoblastoma","valueDescription":"HEP - 155; Liver-Hepatoblastoma","ValueMeaning":{"publicId":"2572666","version":"1","preferredName":"HEP - 155; Liver-Hepatoblastoma","longName":"2572666","preferredDefinition":"A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage. The treatment of choice for hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoblastoma","conceptCode":"C3728","definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABCA-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Liver-Primary-NOS","valueDescription":"LIV - 155; Liver-Primary-NOS","ValueMeaning":{"publicId":"2572667","version":"1","preferredName":"LIV - 155; Liver-Primary-NOS","longName":"2572667","preferredDefinition":"An epithelial or non-epithelial malignant neoplasm that arises from the liver. Representative examples include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Malignant Liver Neoplasm","conceptCode":"C34803","definition":"An epithelial or non-epithelial malignant neoplasm that arises from the liver. Representative examples include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABCB-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lung/Bronchus","valueDescription":"LG - 162.9; Lung/Bronchus","ValueMeaning":{"publicId":"2572668","version":"1","preferredName":"LG - 162.9; Lung/Bronchus","longName":"2572668","preferredDefinition":"A primary or metastatic malignant neoplasm involving the lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Lung Neoplasm","conceptCode":"C7377","definition":"A primary or metastatic malignant neoplasm involving the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8E9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABCC-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymph Nodes","valueDescription":"LN - 196; Lymph Nodes","ValueMeaning":{"publicId":"2572669","version":"1","preferredName":"LN - 196; Lymph Nodes","longName":"2572669","preferredDefinition":"The spread of a malignant neoplasm to the lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Lymph Nodes","conceptCode":"C4904","definition":"The spread of a malignant neoplasm from its original site of growth to lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LISU","dateModified":"2022-08-03","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABCD-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymphoma","valueDescription":"LYM - 196.9; Lymphoma","ValueMeaning":{"publicId":"2572670","version":"1","preferredName":"LYM - 196.9; Lymphoma","longName":"2572670","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABCE-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"MEL - 172; Melanoma","ValueMeaning":{"publicId":"2572671","version":"1","preferredName":"MEL - 172; Melanoma","longName":"2572671","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABCF-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Multiple Myeloma","valueDescription":"MM - 203; Multiple Myeloma","ValueMeaning":{"publicId":"2572672","version":"1","preferredName":"MM - 203; Multiple Myeloma","longName":"2572672","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8ED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD0-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nasopharynx","valueDescription":"NASO - 147.9; Nasopharynx","ValueMeaning":{"publicId":"2572673","version":"1","preferredName":"NASO - 147.9; Nasopharynx","longName":"2572673","preferredDefinition":"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharynx","conceptCode":"C12423","definition":"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8EE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD1-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Neurofibroma","valueDescription":"NF - 237.7; Neurofibroma","ValueMeaning":{"publicId":"2572674","version":"1","preferredName":"NF - 237.7; Neurofibroma","longName":"2572674","preferredDefinition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibroma","conceptCode":"C3272","definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD2-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"NOS","valueDescription":"CA - 199.1; NOS","ValueMeaning":{"publicId":"2572675","version":"1","preferredName":"CA - 199.1; NOS","longName":"2572675","preferredDefinition":"Malignant growth of cells in the peripheral nervous system (PNS)or Autonomic Nervous System (ANS), without specification as to location","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peripheral Nervous System Neoplasm","conceptCode":"C4961","definition":"Malignant growth of cells in the peripheral nervous system (PNS)or Autonomic Nervous System (ANS), without specification as to location","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD3-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ovary-NOS","valueDescription":"OV - 183; Ovary-NOS","ValueMeaning":{"publicId":"2572676","version":"1","preferredName":"OV - 183; Ovary-NOS","longName":"2572676","preferredDefinition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Neoplasm","conceptCode":"C7431","definition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD4-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ovary-Germ Cell","valueDescription":"OV-GC - 183; Ovary-Germ Cell","ValueMeaning":{"publicId":"2572677","version":"1","preferredName":"OV-GC - 183; Ovary-Germ Cell","longName":"2572677","preferredDefinition":"A neoplasm that arises from the ovary and originates from germ cells. Representative examples include teratoma, embryonal carcinoma, yolk sac tumor, and dysgerminoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Germ Cell Tumor","conceptCode":"C3873","definition":"A neoplasm that arises from the ovary and originates from germ cells. Representative examples include teratoma, embryonal carcinoma, yolk sac tumor, and dysgerminoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD5-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ovary-Epithelial","valueDescription":"OV-EP - 183; Ovary-Epithelial","ValueMeaning":{"publicId":"2572678","version":"1","preferredName":"OV-EP - 183; Ovary-Epithelial","longName":"2572678","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD6-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ovary-Stromal","valueDescription":"OV-STR - 183; Ovary-Stromal","ValueMeaning":{"publicId":"2572679","version":"1","preferredName":"OV-STR - 183; Ovary-Stromal","longName":"2572679","preferredDefinition":"A benign or malignant neoplasm that arises from the ovary and is composed of granulosa cells, Sertoli cells, Leydig cells, theca cells, and fibroblasts.  Representative examples include thecoma, fibroma, Sertoli cell tumor, and granulosa cell tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Sex Cord-Stromal Tumor","conceptCode":"C4862","definition":"A benign or malignant neoplasm that arises from the ovary and is composed of granulosa cells, Sertoli cells, Leydig cells, theca cells, and fibroblasts.  Representative examples include thecoma, fibroma, Sertoli cell tumor, and granulosa cell tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD7-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Pancreas","valueDescription":"PANC - 157.9; Pancreas","ValueMeaning":{"publicId":"2572680","version":"1","preferredName":"PANC - 157.9; Pancreas","longName":"2572680","preferredDefinition":"A primary or metastatic malignant tumor involving the pancreas.  Representative examples include carcinoma and lymphoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pancreatic Neoplasm","conceptCode":"C9005","definition":"A primary or metastatic malignant tumor involving the pancreas.  Representative examples include carcinoma and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD8-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Parathyroid","valueDescription":"PTH - 194.1; Parathyroid","ValueMeaning":{"publicId":"2572681","version":"1","preferredName":"PTH - 194.1; Parathyroid","longName":"2572681","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the parathyroid glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Parathyroid Gland Neoplasm","conceptCode":"C9322","definition":"A primary or metastatic malignant neoplasm affecting the parathyroid glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABD9-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Pheochromocytoma","valueDescription":"PHEO - 194.0; Pheochromocytoma","ValueMeaning":{"publicId":"2572682","version":"1","preferredName":"PHEO - 194.0; Pheochromocytoma","longName":"2572682","preferredDefinition":"A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines.  It arises from the chromaffin cells of the adrenal medulla.  Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Gland Pheochromocytoma","conceptCode":"C3326","definition":"A neuroendocrine neoplasm of the sympathetic nervous system that arises from the chromaffin cells of the adrenal medulla and secretes catecholamines. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABDA-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Prostate","valueDescription":"PR - 185.0; Prostate","ValueMeaning":{"publicId":"2572683","version":"1","preferredName":"PR - 185.0; Prostate","longName":"2572683","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-ABDB-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Rectum","valueDescription":"RECT - 154.1; Rectum","ValueMeaning":{"publicId":"2572684","version":"1","preferredName":"RECT - 154.1; Rectum","longName":"2572684","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Rectal Neoplasm","conceptCode":"C7418","definition":"A primary or metastatic malignant neoplasm that affects the rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA47-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Retinoblastoma","valueDescription":"RB - 190.5; Retinoblastoma","ValueMeaning":{"publicId":"2572685","version":"1","preferredName":"RB - 190.5; Retinoblastoma","longName":"2572685","preferredDefinition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoblastoma","conceptCode":"C7541","definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8FA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA48-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Sarcoma","valueDescription":"SARC - 200.0; Sarcoma","ValueMeaning":{"publicId":"2572686","version":"1","preferredName":"SARC - 200.0; Sarcoma","longName":"2572686","preferredDefinition":"A malignant mesenchymal tumor for which a distinct line of differentiation cannot be determined. This term may be used for small biopsy specimens for which adequate tissue is not present for definitive classification.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AC46-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Sarcoma-Ewings","valueDescription":"EW - 200.0; Sarcoma-Ewings","ValueMeaning":{"publicId":"2572687","version":"1","preferredName":"EW - 200.0; Sarcoma-Ewings","longName":"2572687","preferredDefinition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma","conceptCode":"C4817","definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8FC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC63A462-AC47-05FA-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Sarcoma-Osteo","valueDescription":"OSTEO - 200.0; Sarcoma-Osteo","ValueMeaning":{"publicId":"2572688","version":"1","preferredName":"OSTEO - 200.0; Sarcoma-Osteo","longName":"2572688","preferredDefinition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation.  It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor.  It often affects the diaphysis or metaphyseal-diaphyseal portion of long bones.  Clinical findings include pain and a mass in the involved area.  Fever, anemia, leucocytosis, and an increased sedimentation rate are often seen.  X-ray examination reveals osteolytic lesions.  The prognosis depends on the stage, anatomic location, and size of the tumor. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma of Bone","conceptCode":"C4835","definition":"A small round cell bone tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation.  It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor.  It often affects the diaphysis or metaphyseal-diaphyseal portion of long bones.  Clinical findings include pain and a mass in the involved area.  Fever, anemia, leukocytosis, and an increased sedimentation rate are often seen.  X-ray examination reveals osteolytic lesions.  The prognosis depends on the stage, anatomic location, and size of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8FD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA49-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Skin-NOS","valueDescription":"NMSK - 173.0; Skin-NOS","ValueMeaning":{"publicId":"2572689","version":"1","preferredName":"NMSK - 173.0; Skin-NOS","longName":"2572689","preferredDefinition":"A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Skin Neoplasm","conceptCode":"C2920","definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8FE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA4A-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Skin-Squamous cell carcinoma","valueDescription":"SCC - 173.0; Skin-Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2572690","version":"1","preferredName":"SCC - 173.0; Skin-Squamous Cell Carcinoma","longName":"2572690","preferredDefinition":"A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Squamous Cell Carcinoma","conceptCode":"C4819","definition":"A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8FF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA4B-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Skin-Basal Cell Carcinoma","valueDescription":"BCC - 173.0; Skin-Basal Cell Carcinoma","ValueMeaning":{"publicId":"2572691","version":"1","preferredName":"BCC - 173.0; Skin-Basal Cell Carcinoma","longName":"2572691","preferredDefinition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E900-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA4C-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Soft Tissue","valueDescription":"SFT-NOS - 171.9; Soft Tissue","ValueMeaning":{"publicId":"2572692","version":"1","preferredName":"SFT-NOS - 171.9; Soft Tissue","longName":"2572692","preferredDefinition":"A malignant mesenchymal neoplasm arising exclusively from the soft tissues.  Representative examples include soft tissue sarcoma, extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor, and malignant hemangiopericytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Soft Tissue Neoplasm","conceptCode":"C4867","definition":"A malignant neoplasm arising exclusively from the soft tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E901-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA4D-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Testis","valueDescription":"TES - 186.9; Testis","ValueMeaning":{"publicId":"2572693","version":"1","preferredName":"TES - 186.9; Testis","longName":"2572693","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the testis.  Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Neoplasm","conceptCode":"C7251","definition":"A primary or metastatic malignant neoplasm that affects the testis.  Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E902-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA4E-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Thyroid-NOS","valueDescription":"THY - 193.0; Thyroid-NOS","ValueMeaning":{"publicId":"2572694","version":"1","preferredName":"THY - 193.0; Thyroid-NOS","longName":"2572694","preferredDefinition":"A carcinoma arising from the thyroid gland. It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E903-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ICD","id":"EBC19B2D-DA4F-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Thyroid-Follicular","valueDescription":"THY-FOL - 193.0; Thyroid-Follicular","ValueMeaning":{"publicId":"2572695","version":"1","preferredName":"THY-FOL - 193.0; Thyroid-Follicular","longName":"2572695","preferredDefinition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterise the thyroid gland papillary carcinoma are absent.  It is linked to radiation and comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound and fine needle biopsy. Treatment options include: partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Follicular Carcinoma","conceptCode":"C8054","definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterize the thyroid gland papillary carcinoma are absent.  Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E904-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"ZHANGWE","dateModified":"2015-02-23","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA50-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Thyroid-Medullary","valueDescription":"THY-MTC - 193.0; Thyroid-Medullary","ValueMeaning":{"publicId":"2572696","version":"1","preferredName":"THY-MTC - 193.0; Thyroid-Medullary","longName":"2572696","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Medullary Carcinoma","conceptCode":"C3879","definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E905-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA51-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Thyroid-Papillary","valueDescription":"THY-PAP - 193.0; Thyroid-Papillary","ValueMeaning":{"publicId":"2572697","version":"1","preferredName":"THY-PAP - 193.0; Thyroid-Papillary","longName":"2572697","preferredDefinition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  It is linked to radiation exposure and is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound, and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.  Depending on the size and spread of the disease, surgical options include lobectomy, and partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Papillary Carcinoma","conceptCode":"C4035","definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E906-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA65-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Uterine","valueDescription":"UT - 182.0; Uterine","ValueMeaning":{"publicId":"2572698","version":"1","preferredName":"UT - 182.0; Uterine","longName":"2572698","preferredDefinition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uterine Neoplasm","conceptCode":"C3552","definition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E907-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA66-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Uterine-Papillary","valueDescription":"UT-PAP - 182.0; Uterine-Papillary","ValueMeaning":{"publicId":"2572699","version":"1","preferredName":"UT-PAP - 182.0; Uterine-Papillary","longName":"2572699","preferredDefinition":"A high grade, aggressive adenocarcinoma arising from the endometrium.  It is characterized by the presence of complex papillary patterns with cellular budding.  Atypical mitoses, necrosis, and psammoma bodies may be present.  It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia.  It tends to invade deeply into the myometrium and spreads into the lymphatic vessels.  Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Serous Adenocarcinoma","conceptCode":"C27838","definition":"A high-grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E908-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA67-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Uterine-Serous","valueDescription":"UT-SER - 182.0; Uterine-Serous","ValueMeaning":{"publicId":"2572700","version":"1","preferredName":"UT-SER - 182.0; Uterine-Serous","longName":"2572700","preferredDefinition":"A high grade, aggressive adenocarcinoma arising from the endometrium.  It is characterized by the presence of complex papillary patterns with cellular budding.  Atypical mitoses, necrosis, and psammoma bodies may be present.  It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia.  It tends to invade deeply into the myometrium and spreads into the lymphatic vessels.  Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Serous Adenocarcinoma","conceptCode":"C27838","definition":"A high-grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E909-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA68-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Uterine-Papillary/Serous","valueDescription":"UT-PS - 182.0; Uterine-Papillary/Serous","ValueMeaning":{"publicId":"2572701","version":"1","preferredName":"UT-PS - 182.0; Uterine-Papillary/Serous","longName":"2572701","preferredDefinition":"A high grade, aggressive adenocarcinoma arising from the endometrium.  It is characterized by the presence of complex papillary patterns with cellular budding.  Atypical mitoses, necrosis, and psammoma bodies may be present.  It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia.  It tends to invade deeply into the myometrium and spreads into the lymphatic vessels.  Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Serous Adenocarcinoma","conceptCode":"C27838","definition":"A high-grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E90A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA69-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Uterine Sarcoma","valueDescription":"UT-SARC - 200.0; Uterine Sarcoma","ValueMeaning":{"publicId":"2572702","version":"1","preferredName":"UT-SARC - 200.0; Uterine Sarcoma","longName":"2572702","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Sarcoma","conceptCode":"C6339","definition":"A malignant mesenchymal neoplasm arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E90B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA6A-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Waldenstrom's Macroglobulinemia","valueDescription":"WM - 273.3; Waldenstrom's Macroglobulinemia","ValueMeaning":{"publicId":"2572703","version":"1","preferredName":"WM - 273.3; Waldenstrom's Macroglobulinemia","longName":"2572703","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E90C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA6B-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Wilms Tumor","valueDescription":"WILM - 189.0; Wilms Tumor","ValueMeaning":{"publicId":"2572704","version":"1","preferredName":"WILM - 189.0; Wilms Tumor","longName":"2572704","preferredDefinition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E90D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"LUY","dateModified":"2015-02-24","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EBC19B2D-DA6C-603E-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFB66CD6-B3C7-9E73-E040-BB89AD4305D7","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"ONEDATA","dateModified":"2012-11-30","deletedIndicator":"No"},{"value":"Eye","valueDescription":"EYE - 190.9; Eye, part unspecified","ValueMeaning":{"publicId":"3826038","version":"1","preferredName":"EYE - 190.9; Eye, part unspecified","longName":"3826038","preferredDefinition":"A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal gland, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Eye Neoplasm","conceptCode":"C4767","definition":"A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal system, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E25C7C1F-51AE-1CCC-E040-BB89AD434814","latestVersionIndicator":"Yes","beginDate":"2013-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E25C7C1F-51C7-1CCC-E040-BB89AD434814","beginDate":"2013-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-25","modifiedBy":"ONEDATA","dateModified":"2013-07-25","deletedIndicator":"No"},{"value":"Pleura","valueDescription":"PLEURA NOS - 163.9; Pleura, unspecified","ValueMeaning":{"publicId":"3826039","version":"1","preferredName":"PLEURA NOS - 163.9; Pleura, unspecified","longName":"3826039","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the pleura.  A representative example of primary malignant pleural neoplasm is the malignant pleural mesothelioma.  A representative example of metastatic malignant neoplasm to the pleura is metastatic carcinoma that has spread to the pleura from another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pleural Neoplasm","conceptCode":"C3547","definition":"A primary or metastatic malignant neoplasm affecting the pleura.  A representative example of primary malignant pleural neoplasm is the malignant pleural mesothelioma.  A representative example of metastatic malignant neoplasm to the pleura is metastatic carcinoma that has spread to the pleura from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E25C7C1F-51D1-1CCC-E040-BB89AD434814","latestVersionIndicator":"Yes","beginDate":"2013-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/24/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E25C7C1F-51EA-1CCC-E040-BB89AD434814","beginDate":"2013-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-25","modifiedBy":"ONEDATA","dateModified":"2013-07-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ICD:International Classification of Diseases","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"EBC19B2D-D5EE-603E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-01-04","modifiedBy":"KNABLEJ","dateModified":"2017-07-24","changeDescription":"7/24/17 jk added registration status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"7318690","version":"1","longName":"Survival and Follow-Up - CDISC Aligned","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CDISC Aligned NCI Standard Equivalent CDE","type":"CDISC Note","description":"This data element is to be used for CDISC aligned data collection in place of CDE 3834326 from the original NCI Standard CRF Template.","url":null,"context":"NCI Standards"},{"name":"Cause of Death (ICD-9)","type":"Preferred Question Text","description":"Cause of Death (ICD-9)","url":null,"context":"NCI Standards"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"9743D06E-040E-20CE-E053-F662850A71E1","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-13","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Released. AK 2020-6-17; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}